Adeona Pharmaceuticals and Intrexon Announce Worldwide Exclusive Collaboration for Synthetic DNA-based Therapy for Pulmonary Arterial Hypertension For Immediate Release Ann Arbor, MI, & Germantown, MD, November 21, 2011 – Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN), a developer of...

Blacksburg, Virginia, October 11, 2011. Intrexon Corporation, a privately held synthetic biology company, today announced the formation and launch of its Cell Engineering Unit (CEU) in San Diego, CA. The new unit will be under the leadership of the company’s Chief Science Officer and Founder, Thomas D. Reed, Ph.D. As part of the launch, Intrexon simultaneously announced the acquisition of GT Life Sciences, Inc. and the purchase of assets comprising the LEAP cell-processing platform from Cyntellect, Inc. The two transactions provide the foundational technology, facilities, exclusive IP portfolios, and team for the new scientific unit. Terms of the transactions were not disclosed.

NEW YORK, NY (August 30, 2011) — ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) today announced that the first patient has been dosed in a Phase 1 clinical study of ZIN ATI-001, a novel DNA-based therapeutic candidate, in patients with advanced melanoma. ZIN ATI-001 is the second clinical oncology...

Blacksburg, Virginia, June 27, 2011. Intrexon Corporation, a privately held synthetic biology company, today announced the appointment of Glenn E. Nedwin, Ph.D., MBA as President of its Human Therapeutics Division and a Senior Vice President of the corporation.

NEW YORK, NY (June 10, 2011) — ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced today that the U.S. Food & Drug Administration (FDA) has accepted the Company’s investigational new drug (IND) application to begin clinical study of ZIN ATI-001, a novel DNA-based therapeutic candidate also known as Ad-RTS-IL-12 + AL (INXN 2001/1001), in oncology. When initiated, the Phase I study will evaluate safety in addition to immunological and biological effects of the therapeutic candidate in patients with melanoma. ZIN ATI-001 is the second clinical oncology product candidate from the ZIOPHARM-Intrexon Corporation exclusive synthetic biology channel partnership.

SAN DIEGO and FOSTER CITY, Calif., June 6, 2011 — Halozyme Therapeutics, Inc. (Nasdaq: HALO) and Intrexon Corporation, today announced the signing of a worldwide exclusive licensing agreement for the use of rHuPH20 (recombinant human hyaluronidase) in the development of a subcutaneous (under the skin) injectable formulation of Intrexon Corporation’s recombinant human alpha 1-antitrypsin (rHuA1AT). Under terms of the agreement, Halozyme may receive up to $63 million, commencing with an upfront payment of $9 million and total potential future milestone payments of $54 million dependent upon the achievement of clinical and regulatory targets, plus up to 11% royalty on future sales of the combination of rHuA1AT with rHuPH20. The license provides Intrexon Corporation, a next generation synthetic biology company, with exclusivity to alpha 1-antitrypsin, for the indications resulting from A1AT deficiency. Additional terms of the transaction have not been disclosed.

SEATTLE, WA (May 20, 2011) – ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), and Intrexon Corporation announced today that results from two preclinical studies examining the tightly controlled, intra-tumoral expression of a novel protein, interleukin-12 (IL-12), in melanoma, colon, lung, leukemia, breast and pancreatic cancer models in mice, were presented at the 2011 Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), held May 18 – 21 in Seattle, Washington.

Burlingame, CA, May 9, 2011. Intrexon Corporation, a next generation synthetic biology company, today announced an agreement with Novici Biotech LLC in which Intrexon has licensed certain non-exclusive rights to the use of Novici’s patented GRAMMR^® technology for high-resolution genetic reassortment (“gene shuffling”).

Burlingame, CA, April 21, 2011. Intrexon Corporation, a next generation synthetic biology company, today announced the acquisition of Neugenesis Corporation, a California-based company that has developed recombinant technologies and production systems related to Neurospora crassa, an exceptionally versatile fungal organism capable of producing a wide spectrum of proteins and metabolites of commercial interest. Intrexon also announced that the former Neugenesis facility is now the headquarters for Intrexon’s Industrial Products Division.

Research Triangle Park, NC, February 1, 2011. – Intrexon Corporation, a next generation synthetic biology company, today announced the launch of its Agricultural Biotechnology (AgBio) Division in Research Triangle Park, North Carolina and the acquisition of Agarigen, Inc., a North Carolina-based company that has developed a novel, mushroom-based expression platform for the rapid, high yield production of recombinant proteins. Matthew B. Crisp has been appointed Division President and a Senior Vice President of the company. Mr. Crisp was most recently a Managing Director of Third Security, LLC in Radford, Virginia, a globally recognized investment company led by Randal J. Kirk, Intrexon’s Chairman and CEO.

NEW YORK, NY and GERMANTOWN, MD (January 6, 2011) – ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a small molecule late-stage oncology drug development company, and Intrexon Corporation, a next generation synthetic biology company, announced today a global exclusive channel partnership in oncology where ZIOPHARM will develop and commercialize DNA-based therapeutics using Intrexon’s UltraVector® Technology. Under the partnership, ZIOPHARM will utilize Intrexon’s advanced transgene engineering platform for the controlled and precise cellular production of anti-cancer effectors. ZIOPHARM will have rights to Intrexon’s entire human in vivo effector platform within the field of oncology which includes two lead clinical-stage product candidates, one which is in an advanced Phase I study and another which will be the subject of an Investigational New Drug (“IND”) filing during the first half of 2011. ZIOPHARM and Intrexon will host a conference call and audio webcast today, Thursday, January 6th at 5:00 p.m. ET to discuss the global exclusive channel partnership.

Germantown, Maryland, October 7, 2010 – Intrexon Corporation, a privately held synthetic biology company, today announced the appointment of William E. Fogler, Ph.D., as Senior Director of Portfolio Analysis and Planning for its Human Therapeutics Division. Dr. Fogler’s efforts will focus on identifying high value therapeutic opportunities for which Intrexon’s proprietary technologies and capabilities confer an unparalleled advantage.

Thomas J. Goralski, Ph.D., to lead company’s UltraVector® Division Blacksburg, Virginia, January 11, 2010 – Intrexon Corporation, a privately held life sciences company focused on modular DNA control systems, today announced the appointment of Thomas J. Goralski, Ph.D., as...

Maryland facility will also be the headquarters of company’s Human Therapeutics Division Blacksburg, Virginia, September 1, 2009 – Intrexon Corporation, a privately held life sciences company focused on modular DNA control systems for biotherapeutics and other industry sectors, ...